← Back to patent-cliff list
Atropine sulphate (Ocumension Therapeutics)
Tier C — Watch / tradeAtropine sulphate (Ocumension Therapeutics)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：mAChRs
Indications (approved)：近视, 变性近视
Regional status
US
Phase III
2021-04-01
EU
Phase III
2021-04-15
China
Phase III
2022-03-13
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Atropine sulphate (Ocumension Therapeutics)?
Approved indications include: 近视, 变性近视.
When does the Atropine sulphate (Ocumension Therapeutics) patent expire?
No public expiry year is available for Atropine sulphate (Ocumension Therapeutics) yet; this page updates once verified.
How do I get a quote for Atropine sulphate (Ocumension Therapeutics) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06